Ideas. Owned.®

Jeffer Ali

Principal – IP Litigation Chair

Jeff Ali is a Principal at Patterson Thuente IP and the Chair of the firm’s IP litigation team. Jeff is a seasoned litigator with 25 years of experience representing clients in intellectual property enforcement and defense.

Jeff leads a talented group of attorneys helping to solve clients’ business and legal problems both in and out of a courtroom. Much of his work has focused on representing both small and large companies in patent, trademark, copyright and trade secret matters in the pharmaceutical, medical device, software and manufacturing industries.

With a Doctor of Pharmacy degree and real-world experience as a practicing pharmacist, a particular emphasis of Jeff’s career has been representing generic pharmaceutical companies, including some of the world’s largest, in Hatch-Waxman ANDA litigation as companies attempt to get their products to market in the face of name brand companies’ patents.

Jeff is committed to providing access to the legal system for under-resourced individuals. He has performed hundreds of hours of pro bono work and served on the boards of directors for the Volunteer Lawyers Network and the Fund for the Legal Aid Society of Minneapolis. Prior to joining Patterson Thuente IP, Jeff took a 3-year hiatus from private practice to serve indigent tenants through Mid-Minnesota Legal Aid.


  Patent Litigation

  • PENDING: SVL v. Carson Design and Manufacturing Inc, et. al, 0-21-cv-00619 (DMN). Defending mid-sized HVAC products manufacturer in patent infringement and unfair competition case.
  • Donaldson Company, Inc. v. Baldwin Filters, Inc., 0-04-cv-02679 (DMN). Represented plaintiff in a patent infringement dispute between two competitors in the air filters market.

  Trade Secrets Litigation

  • PENDING: Mednet Solutions v. Veeva Systems, Inc., 0-2020-cv-02502 (DMN). Co-counsel representing plaintiff in a trade secret misappropriation case.

   Pharmaceutical/Hatch-Waxman Litigation

  • Forest Labs, et al. v. Teva Pharmaceuticals USA, Inc., et al. Served as lead trial counsel representing world’s largest generic drug company in patent infringement dispute relating to generic company’s attempt to market generic version of $2.2B blockbuster Alzheimer’s drug Namenda XR before patent expiration. An analyst attending the trial reported that the Jeff’s cross examination of the brand company’s main expert witness “drew blood on almost every point.”  After the trial was over, but before decision, the case settled favorably for the generic company under confidential terms.
  • OSI Pharmaceuticals, Inc., Pfizer, Inc. And Genentech, Inc. V. Teva Pharmaceuticals USA, Inc., et al. On a team representing a pharmaceutical company against charges of infringement of compound, polymorph and method patents relating to erlotinib (Tarceva®) in a Paragraph IV Hatch-Waxman case. Client was offered a favorable settlement on the first day of trial.
  • Hoffmann-La Roche v. Teva Pharmaceuticals USA, Inc. Lead trial counsel in a Paragraph IV Hatch-Waxman case representing a pharmaceutical company concerning their ANDA for capecitabine (Xeloda®). Challenged the infringement and validity of listed Orange Book patents; case settled on favorable terms on the eve of the trial.
  • Purdue v. Teva Pharmaceuticals USA, Inc. Part of a team that secured a victory for a large pharmaceutical company in a patent infringement case before a US District Judge in the SDNY. Successfully argued that four of the plaintiff’s patents lacked novelty and/or were obvious; fifth patent was ruled invalid for indefiniteness. Client was able to secure favorable settlement.
  • Celgene v. Teva Pharmaceuticals USA, Inc. Lead trial counsel in a Paragraph IV Hatch-Waxman case over its efforts to introduce a generic version of Focalin® (dexmethylphenidate) into the consumer market. Achieved a successful settlement for the defendant.
  • Astra v. Kremers Urban Development Co. And Schwarz Pharma. Part of a team representing Kremers Urban Development Co. And Schwarz Pharma in support of their ANDA seeking permission to launch a generic version of Prilosec® onto the market. The drug was netting around $10 million per day. Achieved a successful decision for clients in multidistrict litigation, finding no infringement, and permitting clients to introduce a generic version of the drug.

  Pro Bono Litigation

  • Kathryn Eich et al. V. City of Burnsville. With co-counsel: sued city of Burnsville, Minnesota, on behalf of resident of a Burnsville-manufactured home park because of the city’s enforcement of property maintenance code in the park. The city subsequently changed its code due to the lawsuit.

  Other Litigation

  • Annette Nawls v. Timothy Scott McCaffrey. Represented a woman assaulted at Mystic Lake Casino while working as a food and beverage server at a private party. Sued perpetrator for assault, tried the case to a jury and won a judgment of over $300,000.


  • University of Minnesota Law School, Minneapolis, Minnesota
    • J.D. – 1994
    • Honors: cum laude
  • University of Michigan, Ann Arbor, Michigan
    • Pharm. D., Doctor of Pharmacy – 1990


  • Minnesota Super Lawyers (2014 – 2017)
  • Private Practice Pro Bono Lawyer of the Year, Hennepin County Volunteer Lawyers Network

Professional Associations

  • American Intellectual Property Law Association
  • Minnesota Intellectual Property Law Association
  • Minnesota State Bar Association
  • Volunteer Lawyers Network
  • Hon. Jimmie V. Reyna IP Inn of Court

Bar Admissions

  • U.S. Court of Appeals 7th Circuit
  • U.S. District Court District of Minnesota
  • U.S. District Court Eastern District of Wisconsin
  • Minnesota Supreme Court
  • U.S. Patent and Trademark Office
  • U.S. District Court Western District of Wisconsin

Community Involvement

  • University of Minnesota Law School, Intellectual Property Moot Court Judge